Z Alexander Cao Selected Research

CRA 026440

7/2006

CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Z Alexander Cao Research Topics

Disease

7	Neoplasms (Cancer) 01/2022 - 05/2006
3	Colorectal Neoplasms (Colorectal Cancer) 10/2018 - 07/2006
2	Stomach Neoplasms (Stomach Cancer) 08/2022 - 01/2022
2	Microsatellite Instability 10/2018 - 01/2017
2	Breast Neoplasms (Breast Cancer) 01/2017 - 07/2014
1	Adenocarcinoma 01/2022
1	Disease Progression 01/2017
1	Brain Neoplasms (Brain Tumor) 01/2017
1	Carcinogenesis 01/2012
1	Body Weight (Weight, Body) 05/2006

Drug/Important Bio-Agent (IBA)

2	NivolumabIBA 10/2018 - 01/2017
2	Pharmaceutical PreparationsIBA 01/2017 - 07/2014
2	TubulinIBA 07/2006 - 05/2006
2	Histones (Histone)IBA 07/2006 - 05/2006
1	Biomarkers (Surrogate Marker)IBA 08/2022
1	pembrolizumabIBA 01/2022
1	IpilimumabIBA 10/2018
1	Phenobarbital (Luminal)FDA Link 01/2017
1	Immune Checkpoint InhibitorsIBA 01/2017
1	Phosphatidylinositols (Phosphatidylinositol)IBA 07/2014
1	AlpelisibIBA 07/2014
1	dactolisibIBA 01/2012
1	Everolimus FDA Link 01/2012
1	MTOR InhibitorsIBA 01/2012
1	Adenosine Triphosphate (ATP)IBA 01/2012
1	Sirolimus (Rapamycin)FDA Link 01/2012
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2010
1	Angiopoietin-2IBA 01/2010
1	matrigelIBA 01/2010
1	Bevacizumab (Avastin)FDA Link 07/2006
1	CRA 026440IBA 07/2006
1	Hydroxamic Acids (Hydroxamic Acid)IBA 05/2006
1	abexinostatIBA 05/2006
1	Histone Deacetylases (Histone Deacetylase)IBA 05/2006

Therapy/Procedure

3	Therapeutics 01/2022 - 01/2010
3	Drug Therapy (Chemotherapy) 01/2022 - 01/2010
1	Immunotherapy 11/2021
1	Aftercare (After-Treatment) 01/2017